Filing Flows › Health Care › Myriad Genetics (MYGN)
Myriad Genetics (MYGN) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 6, 2026 · Myriad Genetics (MYGN) Q3 2026 earnings results →
Q3 2026 Revenue down 2% year over year to $203M · 22¢ of every $1 of revenue lost · operating margin -19.7%
Myriad Genetics made $203M in Q3 2026 (-2% Y/Y): Cancer Care Continuum $124M, Mental Health $39.5M, Prenatal Health $39.3M. Operating margin -19.7%, net loss $43.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $202.7M in Q3 2026, down 1% year over year and up 6% from the previous quarter. Cancer Care Continuum was the largest line at 61% of revenue. Prenatal Health lost $5.2M year over year (down 12%), 173% of the total change.
Gross margin was 67.9%, down 2.0 points from Q3 2025. Operating costs exceeded revenue by $39.9M, an operating margin of -19.7%. Operating expenses grew 6% against a revenue fall of 1%. The fastest-growing cost line was Sales & marketing (+18%). The quarter ended with a net loss of $43.9M, wider than the previous quarter's $43.2M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $12.6M of depreciation and amortization and $9.2M of share-based compensation. Working capital and other items added $15.6M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$8.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 6, 2026 | $203M | -2% | -19.7% | −$43.9M | −$6.5M |
| Q2 2026 | 10-Q | Jul 31, 2026 | $191M | -10% | -20.4% | −$43.2M | −$8.3M |
| Q1 2026 | 10-Q | May 6, 2026 | $200M | +2% | -15.3% | −$34.1M | −$15.7M |
| Q4 2025 | 10-K | Feb 24, 2026 | $210M | -0.4% | -2.7% | −$7.9M | $10.6M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $206M | -4% | -11.3% | −$27.4M | $21.1M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $213M | +0.8% | -154.5% | −$330M | −$13.6M |
| Q1 2025 | 10-Q | May 7, 2025 | $196M | -3% | -14.8% | −$100K | −$16.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 10% of its revenue · Stated in 10-K (sentence) · source
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. We develop and commercialize molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. Personalized molecular data and digital and virtual consumer trends are converging to transform traditional models of care. We believe that engaging with providers and patients throughout their consumer and patient journey will better enable us to execute our strategies and fulfill our mission.
In its own words, from its 10-K, filed Feb 24, 2026.
Myriad Genetics against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -2% against the peers' median +2%. Operating margin: -19.7% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: Myriad Genetics 10-Q on SEC EDGAR · CIK 899923 · In Vitro & In Vivo Diagnostic Substances
Guidance and outlook
13F: who owns MYGN and who is buying
More on MYGN
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results